Volume 105, Issue 2 pp. 441-444

Human myeloma cells express the CD38 ligand CD31

Antonella Vallario

Antonella Vallario

Dipartimento di Scienze Biomediche e Oncologia Umana, Università di Torino, Ospedale Mauriziano Umberto I, Torino e Istituto per la Ricerca e la Cura del Cancro (IRCC), Candiolo,

Search for more papers by this author
Marco Chilosi

Marco Chilosi

Istituto di Anatomia Patologica, Università di Verona,

Search for more papers by this author
Fausto Adami

Fausto Adami

Dipartimento di Medicina Clinica e Sperimentale, Università di Padova,

Search for more papers by this author
Licia Montagna

Licia Montagna

Istituto di Anatomia Patologica, Università di Verona,

Search for more papers by this author
Silvia Deaglio

Silvia Deaglio

Dipartimento di Genetica, Biologia e Chimica Medica, Università di Torino,

Search for more papers by this author
Fabio Malavasi

Fabio Malavasi

Istituto di Biologia e Genetica, Università di Ancona, Italy

Search for more papers by this author
Federico Caligaris-Cappio

Federico Caligaris-Cappio

Dipartimento di Scienze Biomediche e Oncologia Umana, Università di Torino, Ospedale Mauriziano Umberto I, Torino e Istituto per la Ricerca e la Cura del Cancro (IRCC), Candiolo,

Search for more papers by this author
First published: 17 February 2005
Citations: 39
Dr Federico Caligaris-Cappio Ospedale Mauriziano Umberto I, Largo Turati 62, 10128 Torino, Italy. e-mail: fcaligaris@ mauriziano.it

Abstract

Multiple myeloma (MM) plasma cells (PC) are CD38+. A ligand for CD38 is the adhesion molecule CD31. By flow cytometry and immunocytochemistry we have investigated whether malignant PC co-express CD38 and CD31. All 68 patients studied were CD38+. 14/14 monoclonal gammopathies of undetermined significance (MGUS) and 39/39 plasmacytic MM patients co-expressed CD38 and CD31 at high density. Only 1/11 plasmablastic MM and 1/4 plasma cell leukaemias (PCL) expressed CD31. These data indicated that PC malignancies co-expressed high levels of both CD38 and its ligand CD31, with the exception of plasmablastic MM and PCL.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.